Hannah Jöriβen

Title: The Innovative Contributions of Inventor Hannah Jöriβen

Introduction

Hannah Jöriβen is a prominent inventor based in Essen, Germany. She has made significant contributions to the field of biomedical research, particularly in the development of novel therapeutic agents. With a total of 3 patents to her name, her work focuses on innovative solutions for medical challenges.

Latest Patents

One of her latest patents involves antibodies capable of binding to the coagulation Factor XI and/or its activated form, Factor XIa. This invention relates to methods of use for these antibodies as agents that inhibit platelet aggregation, thereby preventing thrombus formation. Another notable patent is for substituted phenylimidazopyrazoles, which are novel derivatives used for the treatment and prevention of diseases, particularly those involving angiogenic and hyperproliferative disorders. These treatments can be administered as monotherapy or in combination with other therapeutic measures.

Career Highlights

Hannah has worked with leading companies in the pharmaceutical industry, including Bayer Pharma and Seattle Genetics. Her experience in these organizations has allowed her to contribute to groundbreaking research and development in the field of medicine.

Collaborations

Throughout her career, Hannah has collaborated with esteemed colleagues such as Hans-Georg Lerchen and Lars Linden. These partnerships have further enhanced her research and innovation efforts.

Conclusion

Hannah Jöriβen's contributions to the field of biomedical research exemplify her dedication to innovation and improving healthcare solutions. Her patents reflect her commitment to addressing critical medical challenges through scientific advancement.